| Cover - USD ($) | 12 Months Ended | ||
| Jul. 31, 2021 | Nov. 22, 2021 | Jan. 31, 2021 | |
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | Enzo Biochem, Inc. (the “Company”) is filing this Amendment No. 1 to Form 10-K on Form 10-K/A for the fiscal year ended July 31, 2021, in order to amend and restate Part III, Items 10 through 14 of the report on Form 10-K (the “original 10-K”) that we originally filed with the Securities and Exchange Commission (the “SEC”) on October 12, 2021. This Form 10-K/A has been prepared and filed in reliance on General Instruction G to Form 10-K, which provides that registrants may provide the information required by Part III in a definitive proxy statement or an amendment to the Form 10-K filed with the Securities and Exchange Commission (the “SEC”) within 120 days after the end of the fiscal year covered by the report. The Company had initially planned to file the Part III information in a definitive proxy statement. We are filing this Amendment to provide the Part III information in our Form 10-K because a definitive proxy statement containing such information will not be filed by the Company within 120 days of the end of the fiscal year covered by the Form 10-K. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), each item of the original Form 10-K that is amended by this Form 10-K/A is restated in its entirety, and this Form 10-K/A is accompanied by currently dated certifications on Exhibits 31.3 and 31.2 by the Company’s Chief Executive Officer and Chief Financial Officer. The original Form 10-K is therefore amended to (i) delete the reference on the cover of the original Form 10-K to the incorporation by reference of a definitive proxy statement into Part III of such Form 10-K and (ii) revise Part III, Items 10 through 14 of the Company’s original Form 10-K to include information previously omitted from the original Form 10-K. Except as described above, no other changes have been made to the original Form 10-K. The original Form 10-K continues to speak as of October 12, 2021, the date the Company filed the original Form 10-K with the SEC, and other than as expressly indicated in this Form 10-K/A, the Company has not updated the disclosures contained therein to reflect any events that have occurred at a date subsequent to October 12, 2021. Accordingly, this Form 10-K/A should be read in conjunction with the original Form 10-K and the Company’s other reports filed thereafter. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Jul. 31, 2021 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2021 | ||
| Current Fiscal Year End Date | --07-31 | ||
| Entity File Number | 001-09974 | ||
| Entity Registrant Name | Enzo Biochem, Inc. | ||
| Entity Central Index Key | 0000316253 | ||
| Entity Tax Identification Number | 13-2866202 | ||
| Entity Incorporation, State or Country Code | NY | ||
| Entity Address, Address Line One | 527 Madison Ave. | ||
| Entity Address, City or Town | New York | ||
| Entity Address, State or Province | NY | ||
| Entity Address, Postal Zip Code | 10022 | ||
| City Area Code | 212 | ||
| Local Phone Number | 538-0100 | ||
| Title of 12(b) Security | Common Stock, $.01 par value | ||
| Trading Symbol | ENZ | ||
| Security Exchange Name | NYSE | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 126,324,000 | ||
| Entity Common Stock, Shares Outstanding | 48,471,771 |
